• Crohn s disease an inflammatory bowel

  2023-09-01

  

  Crohn’s disease, an inflammatory bowel disease that affects the gastrointestinal (GI) tract, is characterized by a polymorphism in ULK1 autophagy gene due to the presence of single nucleotide polymorphisms (SNPs). Thus, the autophagic process is impaired during the disease. The mutations in the leuc

• Loss of virulence in ACL mutants

  2023-09-01

  

  Loss of virulence in ACL mutants may be caused by defect in vegetative growth and conidial germination, and reduced trichothecene production. However, supplement of potassium acetate restored the defects in germination rate and vegetative growth, but not virulence in wheat heads (Table 2, Fig. 2B),

• The structural analysis of the

  2023-09-01

  

  The structural analysis of the ASK1 activation segment, which was not phosphorylated in the crystal structure, showed interactions mimicking those found in activated kinases. In addition, the isolated unphosphorylated ASK1-CD is active and able to autophosphorylate itself at three sites, Thr813, Thr

• AP was originally described as a heterodimer of

  2023-09-01

  

  AP-1 was originally described as a heterodimer of the bZIP proteins c-Jun and c-Fos. The experiments described here showed that stimulation of TRPV1 channels induced the expression of both of these classical constituents of AP-1. The essential role of both proteins was analyzed in a series of experi

• br Antifungal resistance what is in

  2023-09-01

  

  Antifungal resistance, what is in a name? Antifungal resistance is an emerging and hot topic in the field of medical mycology. Microbiological resistance is identified by determining minimal inhibitory concentrations (MICs) in vitro for a given antifungal and interpreting this value according to

• The advantage of active immunotherapy is

  2023-09-01

  

  The advantage of active immunotherapy is long-term antibody production from short-term drug administration at limited cost. Conversely, immune response may be inconsistent or lacking, especially in older individuals, and adverse reactions—if immunologically based—may also be long-lasting. Initial ex

• Perhaps the first evidence of AMPKs therapeutic ability in

  2023-09-01

  

  Perhaps the first evidence of AMPKs therapeutic ability in DM1 came from Thomas Cooper’s laboratory where they demonstrated that insulin-independent glucose uptake was unaffected in human DM1 muscle EGTA treated with MET, an AMPK activator and first-line therapy for type 2 diabetes mellitus [76]. S

• Treatment of RAW cells with

  2023-09-01

  

  Treatment of RAW264.7 4716 with AP(+)-exosomes caused an increase in their phagocytic activity. In the presence of amastatin, phagocytic activity was not completely suppressed, suggesting that at least two components were responsible for the activity; one of which is aminopeptidase(s). When the act

• Our previous study revealed expression of AhR

  2023-09-01

  

  Our previous study revealed expression of AhR in human parotid gland in cytoplasm of striated duct ABT263 (Drozdzik, Kowalczyk, Urasińska, & Kurzawski, 2013). In a further study we observed regulation of AhR expression and function by its specific inducer, i.e. 2,3,7,8-tetrachlorodibenzo-p-dioxin (T

• The cavity volume of the

  2023-09-01

  

  The cavity volume of the binding pocket may differ not only between species but also among various AhR/ARNT isoforms within a single species. It is noteworthy that even a single amino CHIR-99021 substitution within a binding pocket may result in a change in the cavity volume. This, in turn, may aff

• Medium spiny neurons MSNs in the striatum start from a

  2023-09-01

  

  Medium spiny neurons (MSNs) in the striatum start from a deeply hyperpolarized resting membrane potential, slowly depolarize and show a delayed start of firing during a current injection (Kawaguchi, 1993, Nisenbaum and Wilson, 1995, Planert et al., 2013). The firing pattern during the current inject

• Synthesis pharmacological evaluation for the binding

  2023-09-01

  

  Synthesis, pharmacological evaluation for the binding at hA, hA and hA ARs, and efficacy at hA subtype of the synthesized compounds, together with the assessment of their theoretical ADME properties were the guidelines in this preliminary drug discovery investigation. The synthetic pathways which y

• br Introduction Adenosine deaminase ADA which can

  2023-09-01

  

  Introduction Adenosine deaminase (ADA), which can catalyze the conversion of AD to inosine by removing an amino group, is a key hydrolytic enzyme of purine metabolism (Conway and Cooke, 1939), and plays an important role in an amount of diseases. For example, an increase of ADA activity in serum

• Our second patient years old male a

  2023-09-01

  

  Our second patient, 42years old male, a farmer, was all right when he went to sleep, but noticed drooping of eyelids and swallowing difficulty when he woke up. He later developed flaccid weakness of all four limbs and was quadriplegic when he was wheeled into the emergency room. He was tachypneic an

• For the NSCLC patients with EGFR activating

  2023-08-31

  

  For the NSCLC patients with EGFR-activating mutations, EGFR-TKIs (gefitinib and erlotinib) are effective clinical therapies [21], [22]. However, approximately 10% of patients harboring EGFR-sensitizing mutations exhibit intrinsic resistance, and up to 40% do not attain a major response to treatment

15616 records 240/1042 page Previous Next First page 上5页 236237238239240 下5页 Last page